drugset / Trial / NCT02858973

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers

NCT02858973

Phase 1 Completed 47 enrolled Qurient Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is randomized, double-blind, placebo-controlled, multiple ascending dose study of Q203 in healthy volunteers conducted at one study center in the United States

Timeline

Start
2016-08
Primary completion
2018-05
Completion
2018-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Telacebec Small molecule Oral

Indications

No indication recorded.